Effects of Vitamin D Supplementation on Plasma Aldosterone and Renin—A Randomized Placebo‐Controlled Trial. Issue 7 (21st April 2016)

• Record Type: Journal Article
• Authors: Grübler, Martin R.; Gaksch, Martin; Kienreich, Katharina; Verheyen, Nicolas; Schmid, Johannes; Ó Hartaigh, Bríain W. J.; Richtig, Georg; Scharnagl, Hubert; Meinitzer, Andreas; Pieske, Burkert; Fahrleitner‐Pammer, Astrid; März, Winfried; Tomaschitz, Andreas; Pilz, Stefan
• Is Part Of: Journal of clinical hypertension. Volume 18:Issue 7(2016)
• Page Start: 608
• Page End: 613
• Publication Date: 2016-04-21
• Subjects: Hypertension -- Periodicals; 616.132
• DOI: 10.1111/jch.12825
• Languages: English
• ISSNs: 1524-6175

Abstract

Abstract : Increasing evidence describes a possible interplay between vitamin D insufficiency with increased aldosterone. The authors sought to evaluate the effect of vitamin D supplementation on plasma aldosterone concentration (PAC) in patients with hypertension and 25‐hydroxyvitamin D[25(OH)D] insufficiency. The Styrian Vitamin D Hypertension Trial was a single‐center, double‐blind, placebo‐controlled randomized clinical trial conducted from 2011 to 2014. Two hundred patients with arterial hypertension and 25(OH)D levels <30 ng/mL were enrolled. Study participants were randomized to receive either 2800 IU of vitamin D3 or placebo. The present investigation is a post hoc analysis using analysis of covariance adjusting for baseline differences. A total of 188 participants (mean±standard deviation age, 60.1±11.3 years; 47% women; 25(OH)D, 21.2±5.6 ng/mL) completed the trial. Mean differences between baseline and follow‐up PAC in the control and intervention arm were +3.3 ng/dL and +0.9 ng/dL, respectively ( P =.04). The findings indicate that vitamin D3 supplementation significantly decreases PAC in patients with arterial hypertension and 25(OH)D insufficiency.